BACKGROUND: In this study, we aimed to determine the feasibility of identifying CTCs in patients with HRLPC, using a modified isolation procedure using the CellSearch (Veridex) platform, and to assess the expression of stem cell and epithelial-mesenchymal transition (EMT) markers on the CTCs.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PATIENTS AND METHODS: Thirty-five patients with HRLPC who had chosen prostatectomy for definitive management were prospectively identified. After obtaining consent, four 30-mL blood draws were performed, 2 before surgery and 2 after surgery. The CTC-containing fraction was Ficoll-purified and transferred to a CellSave (Veridex) tube containing dilution buffer before standard enumeration using the CellSearch system. Loss of E-cadherin expression, a marker of EMT, and CD133, a putative prostate cancer stem cell marker, were characterized using the open channel of the CellSearch platform. CTC fragments were also enumerated.
RESULTS: Using the modified methodology, CTCs were detectable in 49% of patients before surgery. Although no correlation between CTC count and biochemical recurrence (BR) was observed, the percentages of CD133 and E-cadherin-positive CTC fragments were associated with BR at 1 year.
CONCLUSION: Our results suggest that further research into the development of CTCs as prognostic biomarkers in HRLPC is warranted.
Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, Kawachi M, Yen Y, Jones JO. Are you the author?
Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA; Department of Molecular Pharmacology, City of Hope Comprehensive Cancer Center, Duarte, CA; Department of Urology, City of Hope Comprehensive Cancer Center, Duarte, CA; Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA; Clinical Trials Office, City of Hope Comprehensive Cancer Center, Duarte, CA; Department of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Reference: Clin Genitourin Cancer. 2014 Sep 22. pii: S1558-7673(14)00207-9.